Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short Interest

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 549,400 shares, an increase of 36.8% from the November 15th total of 401,700 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average daily volume of 72,700 shares, the short-interest ratio is presently 7.6 days.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently bought and sold shares of the business. Rhumbline Advisers acquired a new stake in Gyre Therapeutics during the second quarter worth approximately $123,000. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $166,000. WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics during the 2nd quarter worth $220,000. Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics during the 2nd quarter worth $218,000. Finally, Barclays PLC increased its stake in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares during the period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Price Performance

Shares of GYRE traded down $0.14 during midday trading on Friday, reaching $9.64. The stock had a trading volume of 138,657 shares, compared to its average volume of 73,604. The company’s fifty day simple moving average is $13.14 and its two-hundred day simple moving average is $12.59. Gyre Therapeutics has a 1-year low of $8.26 and a 1-year high of $30.40.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.